Long-term Trial of OPA-15406 Ointment in Adult and Pediatric Patients With Atopic Dermatitis
Status:
Completed
Trial end date:
2020-11-11
Target enrollment:
Participant gender:
Summary
To demonstrate the safety of 1% OPA-15406 ointment in adult patients with AD and of 0.3% and
1% OPA-15406 ointments in pediatric patients with AD administered twice daily for 52 weeks.